New crop of mRNA vaccines aim for accessibility

ABSTRACT

The article discusses the clinical trials of new mRNA vaccines to combat COVID-19 that will be easier to store and cheaper, including one from China in a phase 3 trial. Vaccines produced by the Pfizer-BioNTech and Moderna rely on mRNA to direct cells to produce spike, a protein on SARS-CoV-2's surface, which are of high price and need to be stored at extremely low temperatures.